Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -17.60% is 11% below its 5-year average of -15.81%, around the middle of its 5-year range (-143.56%–82.28%).
7.86% below its 12-month average of -16.32%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -20.27%.
EBITDA MARGIN
-17.60%
EBITDA MARGIN AVG TTM
-16.32%
EBITDA MARGIN AVG 3Y
-6.93%
EBITDA MARGIN AVG 5Y
-15.81%
EBITDA MARGIN AVG 10Y
-26.96%
EBITDA MARGIN AVG 15Y
-26.96%
EBITDA MARGIN AVG 20Y
-26.96%
CURRENT VS TTM AVG
-7.86%
CURRENT VS 3Y AVG
-154.09%
CURRENT VS 5Y AVG
-11.30%
CURRENT VS 10Y AVG
+34.72%
CURRENT VS 15Y AVG
+34.72%
CURRENT VS 20Y AVG
+34.72%
IM Cannabis Corp.
Market Cap
$1.16M
EBITDA Margin
-17.60%
TTM Avg
-16.32%
3Y Avg
-6.93%
5Y Avg
-15.81%
Market Cap
$1.18M
EBITDA Margin
-40873.19%
TTM Avg
-40873.19%
3Y Avg
-21172.28%
5Y Avg
-10780.34%
Market Cap
$1.10M
EBITDA Margin
-6.76%
TTM Avg
-0.42%
3Y Avg
7.09%
5Y Avg
7.09%
Market Cap
$1.02M
EBITDA Margin
-182712.72%
TTM Avg
-182712.72%
3Y Avg
-182712.72%
5Y Avg
-182712.72%
Market Cap
$1.45M
EBITDA Margin
-75.46%
TTM Avg
-92.89%
3Y Avg
-421.55%
5Y Avg
-389.33%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IM Cannabis Corp. (IMCC) | $1.16M | -17.60% | -16.32% | -6.93% | -15.81% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | -40873.19% | -40873.19% | -21172.28% | -10780.34% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | -6.76% | -0.42% | 7.09% | 7.09% |
| Genprex, Inc. (GNPX)vs › | $1.31M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.39M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -182712.72% | -182712.72% | -182712.72% | -182712.72% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.40M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.45M | -75.46% | -92.89% | -421.55% | -389.33% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.46M | N/A | N/A | N/A | N/A |
Gross Margin
13.7%
EBITDA Margin
-17.6%
Operating Margin
-25.9%
Net Margin
-38.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -20.27% |
| 2026-03-31 | -13.58% |
| 2025-12-31 | -21.74% |
| 2025-09-30 | -26.95% |
| 2025-06-30 | 0.95% |
| 2025-03-31 | 4.97% |
| 2024-12-31 | -143.56% |
| 2024-09-30 | 10.11% |
| 2024-06-30 | 22.66% |
| 2024-03-31 | -40.73% |
| 2023-12-31 | -41.45% |
| 2023-09-30 | 23.74% |
| 2023-06-30 | 19.16% |
| 2023-03-31 | 35.33% |
| 2022-12-31 | -63.94% |
| 2022-09-30 | -26.24% |
| 2022-06-30 | -26.77% |
| 2022-03-31 | 82.28% |
| 2021-12-31 | -72.01% |
| 2021-09-30 | -76.65% |
| 2021-06-30 | -85.12% |
| 2021-03-31 | -15.06% |
| 2020-12-31 | -125.00% |
| 2020-09-30 | -7.25% |
| 2020-06-30 | -67.15% |
| 2020-03-31 | 131.34% |
| 2019-12-31 | -98.87% |
| 2019-09-30 | -99.36% |
| 2019-07-31 | 13.72% |
| 2019-04-30 | -0.54% |
| 2018-12-31 | 6.61% |
| 2018-09-30 | 137.69% |
| 2018-07-31 | -4.77% |
| 2018-04-30 | -5.24% |
| 2002-01-31 | 100.00% |
| 2001-10-31 | 100.00% |
| 2001-07-31 | 100.00% |
| 2001-04-30 | 100.00% |
| 2001-01-31 | 100.00% |
